These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20737576)

  • 1. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
    Kantarjian HM; Thomas D; Ravandi F; Faderl S; Jabbour E; Garcia-Manero G; Pierce S; Shan J; Cortes J; O'Brien S
    Cancer; 2010 Dec; 116(24):5568-74. PubMed ID: 20737576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
    O'Brien S; Thomas D; Ravandi F; Faderl S; Cortes J; Borthakur G; Pierce S; Garcia-Manero G; Kantarjian HM
    Cancer; 2008 Dec; 113(11):3186-91. PubMed ID: 18846563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
    Thomas DA; Kantarjian H; Smith TL; Koller C; Cortes J; O'Brien S; Giles FJ; Gajewski J; Pierce S; Keating MJ
    Cancer; 1999 Oct; 86(7):1216-30. PubMed ID: 10506707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.
    Kantarjian HM; Thomas D; Ravandi F; Faderl S; Garcia-Manero G; Shan J; Pierce S; Cortes J; O'Brien S
    Leuk Lymphoma; 2010 Mar; 51(3):475-80. PubMed ID: 20078325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
    Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ
    Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
    Jabbour E; O'Brien S; Huang X; Thomas D; Rytting M; Sasaki K; Cortes J; Garcia-Manero G; Kadia T; Ravandi F; Pierce S; Kantarjian H
    Am J Hematol; 2015 Mar; 90(3):193-6. PubMed ID: 25407953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.
    Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J
    Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
    Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
    J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period.
    Thomas X; Danaïla C; Le QH; Sebban C; Troncy J; Charrin C; Lhéritier V; Michallet M; Magaud JP; Fiere D
    Leukemia; 2001 Dec; 15(12):1811-22. PubMed ID: 11753600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
    Gökbuget N; Stanze D; Beck J; Diedrich H; Horst HA; Hüttmann A; Kobbe G; Kreuzer KA; Leimer L; Reichle A; Schaich M; Schwartz S; Serve H; Starck M; Stelljes M; Stuhlmann R; Viardot A; Wendelin K; Freund M; Hoelzer D;
    Blood; 2012 Sep; 120(10):2032-41. PubMed ID: 22493293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction failure in acute lymphoblastic leukemia of childhood.
    Silverman LB; Gelber RD; Young ML; Dalton VK; Barr RD; Sallan SE
    Cancer; 1999 Mar; 85(6):1395-404. PubMed ID: 10189148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].
    Jia JS; Yang SM; Wang J; Jiang H; Zhao T; Bao L; Shi HX; Lu J; Zhu HH; Lai YY; Jiang B; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):497-502. PubMed ID: 27431075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
    Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
    Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.